entertainment -WSS

entertainment

author：entertainment 2025-09-30 05:07:32 - browse：28

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Brain technologies pose threats that are all too real, experts warn

WSS

What do new weight loss drugs mean for bariatric surgery?

Primary care doctor shortage won't be solved by free med school tuition

Has Bernie Sanders reached the limit of his pharma bullying effort?

Novel spinal cord stimulator treats paralysis without surgery

Black vets could get higher VA benefits if race not used in lung test

Apellis safety probe of eye disease drug centers on injection needle

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Cancer drug shortages should be causing more outrage

Brain technologies pose threats that are all too real, experts warn

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Crowdfunding for medical bills sidesteps core problem, author says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Has Bernie Sanders reached the limit of his pharma bullying effort?

Medical records are filled with copy

PBM executives asked to testify by House panel

Trump demands the U.S. pay no more for drugs than other countries … again

Chemotherapy before breast cancer surgery might fuel metastasis

entertainment

How to make AI work for medicine

Is it ever OK for doctors to lie to their patients?

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Most antidepressants don't work on kids, teens, study finds

NYU Langone launches private ChatGPT for its health care data

Empower primary care with adequate payments and technology

knowledge

Wikipedia

focus

entertainment